Q-omics provides the consensus-scored HMGA1P5 profile across patient tissues and cancer cell-line models. HMGA1P5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HMGA1P5 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, HMGA1P5 RNA expression shows 8,723 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where HMGA1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGA1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGA1P5 survival associations across molecular data types. HMGA1P5 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGA1P5 RNA expression–survival associations across cancer types. High HMGA1P5 expression shows unfavorable associations in BLCA, ACC and KIRC, but favorable associations in UCS, UVM and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for HMGA1P5 RNA expression.
This table summarizes HMGA1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGA1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGA1P5 shows lower tumor expression in HNSC, KIRC, BRCA, KICH, THCA and LUSC. The HNSC box plot shows higher HMGA1P5 RNA expression in normal versus tumor tissue (log2 FC = −0.808, t-test p = .006).
This table shows molecular features associated with HMGA1P5 in patient tissues and cancer cell lines. In patient samples, HMGA1P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
